Inventiva’s (IVA) “Buy” Rating Reaffirmed at HC Wainwright

Inventiva (NASDAQ:IVAGet Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $13.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 413.83% from the stock’s current price.

Several other equities research analysts have also issued reports on the stock. Stifel Nicolaus dropped their price objective on shares of Inventiva from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, November 22nd. UBS Group initiated coverage on shares of Inventiva in a research report on Tuesday, November 12th. They issued a “neutral” rating and a $3.00 price target on the stock.

Check Out Our Latest Research Report on Inventiva

Inventiva Stock Performance

IVA stock traded up $0.23 on Thursday, hitting $2.53. 24,321 shares of the company were exchanged, compared to its average volume of 9,193. Inventiva has a twelve month low of $1.53 and a twelve month high of $4.50. The business’s fifty day moving average is $2.36 and its two-hundred day moving average is $2.35.

Inventiva Company Profile

(Get Free Report)

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

Recommended Stories

Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.